Endocan, also known as ESM-1 (endothelial cell specific molecule-1), is a 50 kDa cysteine-rich
proteoglycan, of which approximately 30 kDa corresponds to a single dermatan sulfate chain.
Endocan was expressed in lung, on the vascular capillary network within alveolar walls, and also
at lower level in kidney. Endocan is a secreted tumor marker that was over-expressed in the
vascular endothelium of renal carcinoma, breast carcinoma, glioma, and non-small cell lung cancer.
The circulating levels of Endocan was elevated in lung cancer and sepsis.
| Amino Acid Sequence of Human Endocan/Endothelial cell-specific molecule 1 : 184 aa, MW 20095 Da, Cellular component: secreted |
| Molecular function: growth factor activity ; Swiss ID: Q9NQ30 |
10 20 30 40 50 60
MKSVLLLTTL LVPAHLVAAW SNNYAVDCPQ HCDSSECKSS PRCKRTVLDD CGCCRVCAAG
70 80 90 100 110 120
RGETCYRTVS GMDGMKCGPG LRCQPSNGED PFGEEFGICK DCPYGTFGMD CRETCNCQSG
130 140 150 160 170 180
ICDRGTGKCL KFPFFQYSVT KSSNRFVSLT EHDMASGDGN IVREEVVKEN AAGSPVMRKW
184
LNPR |
| Amino Acid Sequence of Mouse Endocan / EMS-1 |
Total aa: 184; MW: 20043 Da ; Cellular component: secreted; Molecular function: growth factor activity; Swiss ID: Q9QYY7 |
10 20 30 40 50 60
MKSLLLLTTL LVPLHLGMAW SAKYAVDCPE HCDKTECRSS LRCKRTVLDD CGCCQVCAAG
70 80 90 100 110 120
PGETCYRTVS GMDGVKCGPG LKCHFYSEED DFGDEFGICK DCPYGTFGME CKETCNCQSG
130 140 150 160 170 180
ICDRVTGRCL DFPFFQYAAA KSPSRTSASH TERDSASGDG NAVREEIGEG NAARPSVMKW
184
LNPR |
 |
Immunohistochemical staining for endocan. Lung adenocarcinoma shows a strong anti-endocan staining of endothelial cells in the tumor (A) and peritumoral area (B) compared with a negative staining of normal lung (C). For all images, MEP08 anti-endocan monoclonal antibody staining and hematoxylin counterstaining were done. Magnification, x200. Grigoriu B. D. et al.Clinical Cancer Research Vol. 12, 4575-4582, August 1, 2006
|
 |
Kinetics of induced endocan secretion in HUVECs. A, VEGF and fibroblast growth factor-2 induce endocan secretion. HUVECs at confluence were cultured in RPMI 1640 containing 2% FCS. The supernatants were collected and endocan was evaluated by ELISA. Points, mean of seven separate experiments; bars, SE. Experimental conditions:
|
 |
Endocan as a prognostic factor in NSCLC patients (n = 30). A statistically significant difference was found between groups of patients divided by a cutoff of serum endocan of 1.3 ng/mL for (A) overall survival (P = 0.018, log-rank test) and (B) time to progression (P = 0.02, log-rank test). Solid line, high serum endocan group (endocan, >1.3 ng/mL); dotted line, low serum endocan group. Grigoriu B. D. et al.Clinical Cancer Research Vol. 12, 4575-4582, August 1, 2006
|
Endocan Expression Correlated with Poor Survival in Human Hepatocellular Carcinom |
| Hepatocellular carcinoma (HCC) is the second leading cause of cancer death in China. We aimed to first present the expression of endocan in HCC tissue and its correlation with the clinicopathological features and overall survival of patients with HCC after curative hepatectomy. Immunohistochemical detection of endocan, CD34, and vascular endothelial growth factor (VEGF) were performed on samples from 100 patients with HCC. Endocan protein was expressed in endothelium of HCC tissue in all specimens, but was not expressed in endothelium of pericarcinomatous liver tissue and normal liver tissue. Microvessel density (MVD) denoted by endocan (endocan-MVD) in HCC was correlated with microscopic venous invasion and VEGF expression (P < 0.05). Survival analysis showed that overall survival of patients was inversely associated with endocan-MVD (P < 0.01). Multivariate analysis showed that endocan-MVD was an independent prognostic marker for overall survival of HCC (P < 0.01). In conclusion, endocan-MVD was a significant factor to predict the prognosis of HCC patients after curative hepatectomy. |
Huang GW,et al. Dig Dis Sci. 2008 Jul 1. [Epub ahead of print] |
|
, base values and after addition of 20 ng/mL; 
, VEGF165; 
, fibroblast growth factor-2; 
, tumor necrosis factor-
. HUVECs viability evaluated by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test showed no difference over time in all experimental conditions (data not shown). No statistically significant difference in cell number was found after 96 hours of stimulation as measured by lactate dehydrogenase release after cell lysis. B, dose-dependent inhibition of endocan secretion by a blocking anti-VEGF monoclonal antibody after 48 hours of culture; similar results were obtained at all time points. Experiments were done in quadruplicate. C, typical PCR of endocan mRNA expression in HUVECs at 24 hours after stimulation. Grigoriu B. D. et al.Clinical Cancer Research Vol. 12, 4575-4582, August 1, 2006
Product Name |
Immunogen | Species | Host | Application | Catalog No. |
Quantity |
Price ($) |
|---|---|---|---|---|---|---|---|
| Endocan/ESM-1 ELISA Assay | rm Endocan (NS0) |
Mouse |
Sample Assay |
PS001-30-SM-A |
40 |
40 |
|
| Endocan/ESM-1 Polyclonal Antibody | rm Endocan (NS0) |
Mouse |
Goat |
IHC, WB,N |
PS001-30-AG-01 |
50 ug |
350 |
| Endocan/ESM-1 Monoclonal Antibody | rm Endocan (NS0) |
Mouse |
Rat |
IHC, WB, N |
PS001-30-AG-03 |
100 ug |
260 |
| Endocan/ESM-1 Polyclonal Antibody | rh Endocan (NS0) |
Human |
Goat |
IHC, WB, N |
PS001-30-AG-02 |
50 ug |
350 |